[211at]naat
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2026 (NCT07287748)
Timeline
2020s
- Jan 1, 2026
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- Glutamate carboxypeptidase IIRadiodepletion
FOLH1 radiodepletion
Chemistry & pharmacology
- Payload
- 211-astatine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07287748 | Phase 1 | Jan 1, 2026 | Alpha Fusion Inc., National Cancer Center, Japan |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alpha Fusion Inc. | For profit | 1 | 1 | 1 | 2026 |
| National Cancer Center, Japan | Academic/Hospital | 1 | 0 | 1 | 2026 |
2 organizations
Page 1 / 1